Every 8-K that Schrodinger, Inc. (SDGR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SDGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SDGR filings page.
Schrödinger, Inc. reported Q2 2026 total revenue of $58.9 million, an 8% increase from Q2 2025, with ACV of $29.6 million, a 27% increase and $208 million on a trailing four-quarter basis. Drug discovery revenue rose to $23.0 million, supported by a $10 million collaboration milestone related to the Ajax Therapeutics acquisition, while software revenue declined 10% to $32.5 million as the company accelerated its transition to hosted licensing.
Software gross margin was 71% and operating expenses fell 6% to $74.0 million. Other income was $48.9 million, primarily from a gain associated with Eli Lilly and Company’s acquisition of Ajax Therapeutics, resulting in net income of $6.0 million compared with a $43.2 million net loss a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled $418.8 million.
For 2026, Schrödinger expects ACV of $218–$228 million, representing 10–15% growth, and raised drug discovery revenue guidance to $65–$75 million. The company launched its agentic AI co-scientist Bunsen, expanded a strategic software agreement with Bristol Myers Squibb, signed a global discovery collaboration with Simcere, and highlighted peer-reviewed research validating its physics-based platform.
Schrödinger, Inc. disclosed that it received a cash payment of approximately $57 million in connection with Eli Lilly and Company’s acquisition of Ajax Therapeutics, Inc., a company co-founded by Schrödinger. In addition to this upfront payment, Schrödinger is eligible for further cash payments if Ajax achieves specified clinical and regulatory milestones.
Schrödinger, Inc. reported results of its 2026 annual stockholder meeting. Stockholders approved an amendment to the 2022 Equity Incentive Plan that increases the shares of common stock available for issuance by 3,000,000 shares, supporting future equity-based compensation.
Three Class III directors—Richard A. Friesner, Rosana Kapeller-Libermann and Gary Sender—were elected to three-year terms expiring at the 2029 annual meeting. Stockholders approved, on a non-binding basis, the compensation of named executive officers and ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Schrödinger, Inc. outlined the final separation terms for former Chief Commercial Officer and Global Head of Software Sales and Marketing Mannix Aklian through a transition, separation and release of claims agreement. The deal largely matches benefits previously described in his employment agreement and the company’s executive severance plan.
Mr. Aklian will receive nine months of base-salary continuation and up to 12 months of company-paid COBRA health and dental premiums. He is also entitled to cash bonuses for the first quarter of 2026, prorated bonuses for the second quarter and 2026 annual period, totaling $88,096 before taxes, plus accelerated vesting of the portion of his July 2026 restricted stock unit tranche. These benefits depend on him not revoking the agreement during a seven-day revocation period and complying with ongoing confidentiality, non-solicitation and related obligations.
Schrödinger, Inc. announced a leadership change and reaffirmed its financial outlook. On May 18, 2026, Mannix Aklian ceased serving as Chief Commercial Officer and Global Head of Software Sales and Marketing, effective immediately. Former Executive Vice President, Sales, Paul Davie is returning as interim Chief Commercial Officer and Global Head of Software Sales and Marketing while a search is conducted for a permanent replacement.
The company also reaffirmed its previously issued full-year 2026 and second-quarter 2026 financial and operational guidance that was provided with its first-quarter 2026 earnings release on May 5, 2026. Schrödinger highlights that its outlook and other forward-looking statements are subject to risks, including the ability to retain and hire key personnel and demand for its software platform.
Schrödinger, Inc. reported first quarter 2026 revenue of $58.6 million, down 2% from a year earlier, as it advances a shift to hosted software. Annual contract value (ACV) was $28.4 million for the quarter and $201 million on a trailing four-quarter basis, reflecting 12% growth.
Software revenue declined 21% to $35.6 million, while drug discovery revenue more than doubled to $22.9 million due to accelerated recognition of deferred collaboration revenue and one program’s discontinuation. Net loss was $60.0 million, or $0.81 per share, and adjusted EBITDA was a loss of $37.7 million.
The company ended the quarter with $406 million in cash, cash equivalents, restricted cash and marketable securities and reaffirmed 2026 guidance, including ACV of $218–$228 million and drug discovery revenue of $55–$65 million. Schrödinger also highlighted its upcoming agentic AI “co-scientist” Bunsen and the announced up to $2.3 billion sale of co-founded Ajax Therapeutics, in which it held a 5.8% equity stake as of year-end 2025.
Schrödinger, Inc. appointed Therese Abrams as its principal accounting officer effective March 8, 2026. She has been the company’s Vice President, Corporate Controller since July 2025 and previously held several senior finance and revenue roles at Schrödinger and other companies. She is a certified public accountant with a B.S. in Accounting from Oregon State University.
The company states there is no arrangement or understanding with any other person regarding her designation, no related-party transactions requiring disclosure, and no changes to her compensation in connection with the new role. Former Chief Accounting Officer and principal accounting officer Jenny Herman transitioned from that position on March 6, 2026 and will remain employed through April 10, 2026 to support the transition.
Schrödinger, Inc. reported strong 2025 growth while still operating at a loss. Full-year revenue reached $255.9 million, up 23.3%, driven by $199.5 million of software revenue (up 10.6%) and drug discovery revenue of $56.4 million, more than double the prior year. Net loss narrowed to $103.3 million from $187.1 million, and year-end cash, cash equivalents, restricted cash and marketable securities totaled $402.3 million.
In the fourth quarter, revenue was $87.2 million and the company generated $32.5 million of net income versus a loss a year earlier, helped by $50.1 million of other income. Schrödinger is accelerating a shift from upfront on‑premise licenses to hosted, ratable software contracts, which it expects will pressure reported software revenue in the short to medium term but leave ACV and cash flow unchanged.
For 2026, management expects software ACV of $218–$228 million (10–15% growth) and drug discovery revenue of $55–$65 million, with operating expenses below 2025. The company is targeting positive adjusted EBITDA by the end of 2028 as hosted software becomes the dominant model and software gross margins return to the high‑70% range.
Schrödinger, Inc. (SDGR) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference in this report.
The company states the information in this report, including Exhibit 99.1, is being furnished, not filed under the Exchange Act, which means it is not subject to Section 18 liability and will not be incorporated into other filings unless specifically referenced. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
Schrödinger, Inc. filed details of its separation and release of claims agreement with former Executive Vice President and Chief Financial Officer Dr. Geoffrey Porges, following his previously disclosed departure. The agreement confirms severance terms that are described as substantially comparable to those in his 2022 employment agreement and the company’s executive severance plan.
Under the agreement, Dr. Porges will receive salary continuation for nine months, company-paid portions of COBRA health and dental premiums for up to 12 months, and accelerated vesting of the stock option award granted when he joined the company. He is also eligible for a prorated 2025 annual bonus, an extension of the post-separation exercise period for his vested stock options, and a lump-sum payment if he joins a new employer’s health plans before the COBRA period ends.
All benefits are conditioned on Dr. Porges not revoking the agreement during a seven-day revocation period and complying with ongoing obligations, including confidentiality, inventions, non-solicitation, and mutual non-disparagement and release of claims between him and the company.
Schrödinger, Inc. (Nasdaq: SDGR) filed an 8-K disclosing the voting results of its 2025 Annual Meeting held on 18 June 2025. Shareholders acted on three routine corporate-governance items.
- Board elections (Proposal 1): All four Class II directors—Jeffrey Chodakewitz, Michael Lynton, Nancy A. Thornberry and Bridget van Kralingen—were re-elected for terms ending at the 2028 meeting. Support ranged from 73% to 99%, with Michael Lynton receiving the lowest approval (32.4 million “For” versus 12.3 million “Against,” or c. 27.5% opposition).
- Say-on-Pay (Proposal 2): The non-binding advisory vote on executive compensation passed with 50.8 million votes For and 3.0 million Against (≈94.4% support when limited and common stock are combined).
- Auditor ratification (Proposal 3): KPMG LLP was reaffirmed as independent auditor for FY 2025 with 61.4 million votes For and only 0.3 million Against (≈99.5% support).
No other material transactions, earnings data, or strategic changes were reported in this filing.